

P&T Committee Meeting Minutes

Subject:	Louisiana Department of Health and Hospitals Medicaid Pharmaceutical and Therapeutic Committee Meeting
Location:	628 North Fourth Street Baton Rouge, LA Bienville Building Room 118
Date:	November 2, 2016
Members Present:	<ul style="list-style-type: none"> ▪ Harold Brandt, MD ▪ Jeff Deyo, MD ▪ Martha Harris, PharmD ▪ James Lu, MD ▪ Ed Mader, MD ▪ Catherine McDonald, MD ▪ Fred Mills (Senator) ▪ Ben Orlando ▪ J. Rogers Pope (Representative) ▪ Neil Wolfson, MD ▪ Marty R. McKay, RPh
DHH Pharmacy Program Staff Present:	<ul style="list-style-type: none"> ▪ Melwyn Wendt, RPh ▪ Germaine Becks-Moody, PhD, BHSF Program Manager ▪ Sue Fontenot, RPh ▪ Paul Knecht, RPh ▪ Kim Sullivan ▪ SreyRam Kuy, MD, MHS
Contractors Present:	<ul style="list-style-type: none"> ▪ Nina Bandali, PharmD, Magellan Medicaid Administration ▪ Jennifer Pickett, Certified Court Reporter
Others Present:	Presenters are listed in the minutes and sign in sheets and others in attendance from DHH, Bureau of Health Services Financing, Pharmacy Benefits Section upon request.

Opening Remarks

While waiting on a quorum, Dr. SreyRam Kuy, presented “The Opioid Crisis Symposium.” She felt it was important to spend some time on the opioid crisis situation in the U.S. Sales of prescription opioids in the U.S. quadrupled from 1999 to 2014. In 2012, 259 million prescriptions were written for opioid pain medication in the U.S. Typically, abuse starts with prescription drugs. In 2013, Louisiana ranked first in the U.S. for proportion of opioids prescribed per capita among all 50 states. The number of overdose deaths outnumber motor vehicle deaths. Top sources for prescription painkillers were friends or family.

What is Louisiana Medicaid currently doing to combat opioid abuse?

- Non-opioid Pain Treatment Options
- Substance Abuse Rehab
- Pharmacy “Lock-In” Program
- Pharmacy Monitoring Program (PMP)
- Prevention of Prescription Duplication
- Prevention of Early Refills
- Substance Use Disorder Prescription Benefits

These are great first steps, but not enough. Louisiana leads the U.S. in this opioid epidemic. We need to learn others’ successful strategies, for example, the State of Washington decreased opioid overdose deaths by 37%. This was done by the following:

- Opioid Limits*
- Opioid Dosing Guidelines*
- Collaboration between agencies*
- Pain Conference*
- Prescription Monitoring Program*
- Education for providers (free CME, dose calculators, websites)
- Metrics for tracking outcomes and progress
- Incentivized non-opioid alternatives

*Already or Planned Adoption by Louisiana Medicaid

How do we proceed next? Dr. Tom Frieden, CDC Director, stated “The prescription overdose epidemic is doctor-driven. It can be reversed in part by doctors.”

Future Medicaid strategies consist of the following:

- Opioid prescription quantity limits (staged implementation) for adults and children discussed at the Pharmacy Drug & Utilization Review Board on September 21, 2016. There will be certain exemptions for cancer, palliative care, and terminal illnesses.
- Clinical pre-authorization for long-acting opioids
- Guidelines on opioid dosing threshold based on morphine-equivalence
- Initiate coverage of Medication Assisted Therapy (MAT)/methadone coverage
- Reduce “red tape” for provider by automation of over-rides and exemptions

Dr. Kuy thanked everyone for the time spent on this very serious epidemic. She emphasized that together we can make Louisiana healthier and safer.

Call to Order

Marty R. McKay, Chairman, called the meeting to order at 9:57 a.m. after a quorum was reached with 11 members. He stated that this meeting will be conducted in compliance with the Open Meetings Law.

Parliamentary Business

- A. Introduction of Members.** A. Committee members and staff introduce themselves.
- B. Additional Agenda Items.** The Chair entertained requests for additional agenda items. Mr. Orlando moved to add the class Ophthalmic Antibiotic/Steroid Combinations as number 58 on the agenda. The motion was seconded by Dr. Wolfson. Mr. McKay explained that the reason this was added that it was omitted from the agenda. A roll call vote was taken; all affirmative and no objections. Mr. McKay called for public comment on any non-agenda items. Hearing none, Mr. McKay continued on with the business on hand.
- C. Approval of Minutes.** Mr. McKay asked for a motion to approve the minutes from May 4, 2016. There were no objections to approving the minutes. Mr. McKay asked for a motion to reorder the agenda as necessary. There were no objections.

Ethics Reminder

Code of Ethics. Ms. Sullivan went over the code of ethics. Members are bound by the governmental code of ethics. She suggested for all to go to the Board’s website, <http://www.ethics.state.la.us>, for webinars. If anyone has personal ethical questions, please contact Kim Sullivan at Kimberly.sullivan@la.gov.

Reports

- A. Melwyn Wendt from DHH provides report.** Ms. Wendt stated that the list of prior authorizations, the monthly report that was there for the fee-for-service claims and the PDL list were all included in the packet.

New Business

A. Therapeutic Class Reviews of Drug Classes/Drug Manufacturer Testimony

In accordance with state law and the P&T Committee's bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee's review.

Presenter	Representing	Drug/Issue
Christopher Cant	Allergan	Namzaric, Vraylar
Michael Barber	Sunovion	Latuda
Jason Swartz	Otsuka	Rexulti
Vicki Ryan	Mental Health America of Louisiana	Medications for mental illness
Richard Fiscella	Allergan	Lumigan
Corey Hebert	Rhodes Pharma	Aptensio XR
Pat Trifunov	Tris Pharma	Dyanavel XR
George Kehner	Neos Therapeutics	Adzenys XR ODT

****NOTE:** Names of speakers who were present and yielded their time back were not captured.

Alzheimer's Agents

Mr. Orlando makes the motion to accept. Dr. Mader seconds the motion. Dr. Brandt asked the speaker if the cost of care of the combination of the dual drugs of Namzaric would be lower per month than the two combined generics. Mr. Cant did not have such data. There was no objection to the motion.

Committee recommendations for the PDL are:

- Donepezil ODT
- Donepezil tablet
- Exelon
- Memantine tablet, tablet dose pack

Antidepressants, Other

Dr. Wolfson makes the motion to accept. Mr. Orlando seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- All forms of generic bupropion and bupropion SR
- Mirtazapine and ODT
- Pristiq
- Trazodone
- Venlafaxine

- Venlafaxine ER capsule

Antidepressants, SSRI

Mr. Orlando makes the motion to accept. Dr. McDonald seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Citalopram tab and soln
- Escitalopram tab
- Fluoxetine caps, soln
- Fluvoxamine
- Paroxetine tab
- Sertraline tab and soln

Antihistamines, Minimally Sedating

Dr. Wolfson makes the motion to accept. Mr. Orlando seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Cetirizine
- Levocetirizine
- Loratadine

Antihypertensives, Sympatholytics

Mr. Orlando makes the motion to accept. Dr. Harris seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Catapres-TTS patch
- Clonidine generic
- Guanfacine
- Methyldopa

Antihyperuricemics

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Allopurinol

- Probenecid
- Probenecid combination with colchicine

Antiparkinson's Agents

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Amantadine
- Benztropine
- Carbidopa/levodopa
- Carbidopa/levodopa ER
- Carbidopa/levodopa/entacapone
- Pramipexole
- Ropinirole
- Selegiline tab/cap
- Trihexyphenidyl tab/elixir

Antipsoriatics, Oral

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Acitretin

Antipsoriatics, Topical

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Calcipotriene cream, ointment, and solution

Antipsychotics

Dr. Brandt asked if additional consideration can be given to the generic aripiprazole. There was a motion on the floor by Mr. Orlando and seconded by Dr. Wolfson. Mr. McKay asked if Magellan had considered the generic since the price is dropping out. Dr. Bandali responded that other cost-effective agents are available, and aripiprazole can be obtained with a prior authorization (PA) that is rather easy to get. Dr. Brandt stated he sees people who are suicidal to no longer suicidal in a matter of four days because of aripiprazole. Dr. Brandt offered a substitute motion; seconded by

Mr. Orlando. Dr. McDonald felt it was a good idea to add aripiprazole. A vote was taken to add aripiprazole to the PDL.

Dr. McDonald didn't feel that Latuda needed to be added. Dr. Wolfson questioned if it really does take 2 days for a PA. Ms. Wendt stated that PAs are handled by the University of Louisiana at Monroe for fee-for-service, and a PA request must be turned around in 24 hours, most of which are completed faster than 24 hours. Senator Mills asked how many denials take place on PA requests. Ms. Wendt stated the percentage of denials is very small especially when there is justification for the drug. Dr. Brandt commented on the sheer magnitude of PAs that his office sees. Ms. Wendt stated that there are 5 MCOs, and they too must turn around a PA in 24 hours. Further discussion ensued on filling emergency supplies if Medicaid was closed to approve the PA.

There were no objections to the motion to add aripiprazole.

Committee recommendations for the PDL are:

- Abilify Maintena
- Amitriptyline/perphenazine oral
- Aripiprazole tab
- Aristada
- Chlorpromazine oral
- Clozapine oral
- Fluphenazine tab/inj
- Geodon IM
- Haloperidol lactate conc/oral/inj
- Haloperidol decanoate inj
- Invega Sustenna
- Invega Trinza
- Loxapine oral
- Olanzapine tab/ODT
- Orap
- Perphenazine oral
- Quetiapine oral
- Risperdal Consta inj
- Risperidone tab/soln
- Seroquel XR
- Thioridazine oral
- Thiothixene oral
- Trifluoperazine oral
- Ziprasidone cap

Anxiolytics

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- buspirone
- lorazepam

Bile Salts

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Ursodiol tablet

Bronchodilators, Beta Agonist

Dr. Wolfson makes the motion to accept. Dr. McDonald seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Albuterol nebulizer solutions – all strengths
- Albuterol tab/syrup
- ProAir HFA
- Proventil HFA
- Serevent
- Terbutaline oral

COPD Agents

Mr. Orlando makes the motion to accept. Dr. Harris seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Atrovent HFA
- Combivent Respimat
- Ipratropium/Albuterol combination nebulizer
- Ipratropium nebulizer
- Spiriva

Cytokine and CAM Antagonists

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. Dr. Deyo asked for a comment on Enbrel being nonpreferred. Dr. Bandali pointed out the utilization and the consideration of clinical and financial data. There was no objection to the motion.

Committee recommendations for the PDL are:

- Cosentyx
- Humira

Emollients

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Ammonium lactate cream/lotion
- Lactic Acid cream/lotion

Epinephrine, Self-Injected – new class for review

Mr. Orlando asked if there were any quantity limits on these agents. Ms. Wendt responded that there were no limits for fee-for-service but can be brought up in the drug utilization review. Mr. Orlando makes the motion to accept. Dr. Harris seconds the motion. Thereafter, discussion took place on the availability of the generic as well as the pricing differential between brand and generic; also, no substitution for the generic being allowed if the prescription was written for the brand. The discussion continued on the cost impact to the class if the brand was made nonpreferred. Dr. Wolfson stressed that every effort should be made to get the generic due to this abusive situation. There was no objection to the motion to add both the brand and generic.

Committee recommendations for the PDL are:

- Epinephrine (generic for Adrenaclick)
- Epipen

Erythropoiesis Stimulating Proteins

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Aranesp
- Procrit

Glucocorticoids, Inhaled

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Advair Diskus
- Asmanex
- Dulera
- Pulmicort Respules 0.25 mg, 0.5 mg, 1 mg
- Qvar

- Symbicort

Histamine II Receptor Blockers

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Famotidine tabs
- Ranitidine syrup and tabs

Immunomodulators, Atopic Dermatitis

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Elidel

Immunomodulators, Topical

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Imiquimod

Intranasal Rhinitis Agents

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Fluticasone
- Ipratropium nasal
- Patanase

Leukotriene Modifiers

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Montelukast tab/chew tab

Neuropathic Pain

Dr. Wolfson makes the motion to accept. Mr. Orlando seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Duloxetine
- Gabapentin caps/tab
- Lidocaine patch
- Neurontin solution

NSAIDS

Mr. Orlando makes the motion to accept. Dr. Mader seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Diclofenac sodium and SR
- Ibuprofen tab and susp
- Indocin susp
- Indomethacin caps
- Ketorolac
- Meloxicam tab and susp
- Nabumetone
- Naproxen tab, susp and naproxen EC
- Sulindac
- Voltaren topical gel

Ophthalmic Antibiotic/Steroid Combinations

Mr. Orlando makes the motion to accept. Dr. Harris seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Neomycin/polymyxin B/Dexamethasone combination
- Sulfacetamide/Prednisolone combination
- TobraDex ointment and suspension

Ophthalmic Antibiotics

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the **PDL** are:

- Bacitracin/polymyxin B sulfate oint
- Bleph-10
- Ciprofloxacin soln
- Erythromycin
- Gentamicin drops/oint
- Ilotycin
- Moxeza
- Neomycin/polymyxin/gramicidin
- Ofloxacin
- Polymyxin/trimethoprim
- Sulfacetamide soln
- Tobramycin
- Vigamox

Ophthalmics, Anti-Inflammatory/Immunomodulator – new class for review

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the **PDL** are:

- Restasis

Ophthalmics for Allergic Conjunctivitis

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the **PDL** are:*

- Alrex
- Cromolyn
- Olopatadine
- Pataday
- Pazeo

Ophthalmic Anti-inflammatories

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the **PDL** are:*

- Dexamethasone
- Diclofenac
- Durezol
- Fluorometholone
- Flurbiprofen

- Ilevro
- Ketorolac and LS

Ophthalmics, Glaucoma Agents

Dr. Wolfson makes the motion to accept. Dr. Orlando seconds the motion. There was no objection to the motion.

Committee recommendations for the **PDL** are:

- | | |
|---------------------------------------|---------------|
| • Alphagan P 0.15% | • Levobunolol |
| • Brimonidine | • Pilocarpine |
| • Carteolol | • Simbrinza |
| • Combigan | • Timolol |
| • Dorzolamide and Dorzolamide/timolol | • Travatan-Z |
| • Latanoprost 2.5 mL | |

Otic Anti-infectives & Anesthetics

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the **PDL** are:*

- Acetic Acid
- Acetic Acid HC

Otic Antibiotics

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the **PDL** are:*

- Ciprodex
- Neomycin/Polymyxin/Hydrocortisone solution/suspension

Progestational Agents

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the **PDL** are:*

- Makena MDV & SDV

Sedative Hypnotics

Mr. Orlando makes the motion to accept. Dr. McDonald seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Temazepam
- Triazolam
- Zolpidem

Smoking Cessation

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. Dr. Wolfson asked about the large settlement made in the tobacco case that affected Louisiana residents. Dr. Brandt responded that the settlement is limited to people who started smoking prior to 1988. They will have full coverage from the trust settlement. Dr. Wolfson emphasized that physicians should be educated and take advantage of this. He expressed his concern as to why Medicaid should pay for the same thing that a settlement has already been made for. Senator Mills suggested reaching out to the trust expansion funds and partnering with the trust to see what opportunities are out there. He recommended a report back to the Committee. There was no objection to the motion.

Committee recommendations for the PDL are:

- Bupropion SR
- Chantix and Chantix Dose Pack
- Nicotine gum, patch

Steroids Topical, High Potency

Dr. Wolfson makes the motion to accept. Mr. Orlando seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Betamethasone dipropionate/prop gly cream
- Betamethasone valerate cream/lotion/ointment
- Triamcinolone acetonide cream/lotion/ointment

Steroids Topical, Low Potency

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Alclometasone dipropionate cream/ointment
- Hydrocortisone cream//lotion/ointment

- Hydrocortisone/mineral oil/petrolatum combination

Steroids Topical, Medium Potency

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Fluticasone propionate ointment/cream
- Hydrocortisone butyrate soln
- Mometasone furoate cream/ointment/soln
- Prednicarbate cream

Steroids Topical, Very High Potency

Dr. Wolfson makes the motion to accept. Mr. Orlando seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Clobetasol emollient
- Clobetasol propionate cream, gel, oint, soln
- Halobetasol cream/ointment

Stimulants and Related Agents

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. Dr. Mader questioned why Provigil and Nuvigil were not recommended. Further discussion took place on which product to add. There was an amended motion to add modafinil. There was no objection to the motion.

Committee recommendations for the PDL are:

- Adderall XR
- Amphetamine Salt Combo Immediate Release
- Dexmethylphenidate
- Dextroamphetamine
- Focalin XR
- Guanfacine ER
- Metadate CD
- Methylphenidate IR and ER (generic for Concerta)
- Modafinil
- ProCentra
- Quillichew ER

- Quillivant XR
- Strattera
- Vyvanse

II. Single Drugs

The new drug reviews or single drug reviews are on products that have come to the market since the last review of the class.

In accordance with state law and the P&T Committee’s bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee’s review.

Presenter	Representing	Drug/Issue
Christopher Cant	Allergan	Byvalson
**NOTE: Names of speakers who were present and yielded their time back were not captured.		

The single drugs were reviewed and a recommendation was made. P&T Committee recommendations follow:

Angiotensin Modulator Combinations

Mr. Orlando made the motion to accept. Dr. Wolfson seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Byvalson

Angiotensin Modulators

Mr. Orlando made the motion to accept. Dr. Wolfson seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Qbreliis

Analgesics, Narcotics Long

Mr. Orlando made the motion to accept. Dr. Wolfson seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Xtampza ER

Antiemetic/Antivertigo Agents

Mr. Orlando made the motion to accept. Dr. Wolfson seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Emend Powder Packet

Antifungals, Topical

Mr. Orlando made the motion to accept. Dr. Wolfson seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Loprox Kit

Antimigraine Agents, Triptans

Mr. Orlando made the motion to accept. Dr. Wolfson seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Onzetra Xsail
- Non-prefer Zembrace Symtouch
- Non-prefer Migranow Kit

GI Motility, Chronic

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Relistor

Hepatitis C

Mr. Orlando made the motion to accept. Dr. Wolfson seconded the motion. Mr. McKay asked the Department for their thoughts. Ms. Wendt stated that they are in agreement with Magellan's recommendations. The Department has had extensive conversations with Magellan. Dr. Bandali commented that this is a class that is closely watched by Magellan. There was no objection to the motion.

Committee recommendations for the PDL are:

- Prefer Viekira XR

- Prefer Epclusa for genotypes 2 & 3 only

Hypoglycemics, Incretin Mimetics/Enhancers

Mr. Orlando made the motion to accept. Dr. Wolfson seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Jentadueto XR

Lipotropics, Other

Mr. Orlando made the motion to accept. Dr. Mader seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Repatha Pushtronex

Multiple Sclerosis Agents

Mr. Orlando made the motion to accept. Dr. Wolfson seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Zinbryta

Opiate Dependence Treatment

Mr. Orlando made the motion to accept. Dr. Wolfson seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Probuphine

Tetracyclines

Mr. Orlando made the motion to accept. Dr. Deyo seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Doryx MPC

Other Business

None

Proposed Therapeutic Classes to be Reviewed at Next Meeting

Therapy classes to be reviewed for the April 2017 meeting will be posted on the DHH Medicaid Pharmacy and Therapeutics Committee page as “Agenda.”

Next Meeting Date

The next committee meeting is scheduled for April 26, 2017. Mr. McKay requested that the members go back and look at their calendars.

Adjournment

The meeting adjourned at 12:06 p.m